S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
Log in

Supernus Pharmaceuticals Stock Forecast, Price & News

+0.43 (+1.49 %)
(As of 01/15/2021 12:00 AM ET)
Today's Range
Now: $29.22
50-Day Range
MA: $24.00
52-Week Range
Now: $29.22
Volume690,133 shs
Average Volume617,043 shs
Market Capitalization$1.54 billion
P/E Ratio13.22
Dividend YieldN/A
Supernus Pharmaceuticals, Inc., a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in neurology and psychiatry in the United States. The company offers Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and in children 6 to 17 years of age; and Trokendi XR, an extended release topiramate, which is used for the prophylaxis of migraine headache, as well as for the treatment of epilepsy. Its product candidates comprise SPN-812, a viloxazine hydrochloride, which has completed phase III clinical trial that is used for the treatment of attention deficit hyperactivity disorder (ADHD); SPN-809, a viloxazine hydrochloride, which is in phase II ready clinical trial for the treatment of depression; SPN-604 extended release oxcarbazepine, which is in phase III clinical trial for the treatment of bipolar disorder; and SPN-817 that is in phase I clinical trial to treat severe pediatric epilepsy disorders. The company markets its products through pharmaceutical wholesalers and distributors. It has a development and option agreement with Navitor Pharmaceuticals, Inc. to conduct a phase II clinical program for NV-5138 in treatment-resistant depression. Supernus Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Rockville, Maryland.
Supernus Pharmaceuticals logo


Overall MarketRank

1.42 out of 5 stars

Medical Sector

463rd out of 1,556 stocks

Pharmaceutical Preparations Industry

228th out of 638 stocks

Analyst Opinion: 1.2Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.3 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:SUPN



Sales & Book Value

Annual Sales$392.76 million
Cash Flow$3.64 per share
Book Value$11.35 per share


Net Income$113.06 million


Market Cap$1.54 billion
Next Earnings Date2/23/2021 (Estimated)
+0.43 (+1.49 %)
(As of 01/15/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SUPN News and Ratings via Email

Sign-up to receive the latest news and ratings for SUPN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Supernus Pharmaceuticals (NASDAQ:SUPN) Frequently Asked Questions

How has Supernus Pharmaceuticals' stock price been impacted by Coronavirus?

Supernus Pharmaceuticals' stock was trading at $16.15 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, SUPN shares have increased by 80.9% and is now trading at $29.22.
View which stocks have been most impacted by COVID-19

Is Supernus Pharmaceuticals a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Supernus Pharmaceuticals in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" Supernus Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SUPN, but not buy additional shares or sell existing shares.
View analyst ratings for Supernus Pharmaceuticals
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Supernus Pharmaceuticals?

Wall Street analysts have given Supernus Pharmaceuticals a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Supernus Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Supernus Pharmaceuticals' next earnings date?

Supernus Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, February 23rd 2021.
View our earnings forecast for Supernus Pharmaceuticals

How were Supernus Pharmaceuticals' earnings last quarter?

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) issued its earnings results on Tuesday, November, 3rd. The specialty pharmaceutical company reported $0.74 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.27 by $0.47. The specialty pharmaceutical company earned $155.10 million during the quarter, compared to analyst estimates of $130.76 million. Supernus Pharmaceuticals had a return on equity of 19.44% and a net margin of 27.85%. The business's revenue was up 52.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.54 earnings per share.
View Supernus Pharmaceuticals' earnings history

What guidance has Supernus Pharmaceuticals issued on next quarter's earnings?

Supernus Pharmaceuticals issued an update on its FY 2020 After-Hours earnings guidance on Tuesday, November, 3rd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $500-525 million, compared to the consensus revenue estimate of $486.54 million.

What price target have analysts set for SUPN?

3 Wall Street analysts have issued 12 month target prices for Supernus Pharmaceuticals' stock. Their forecasts range from $24.00 to $31.00. On average, they anticipate Supernus Pharmaceuticals' share price to reach $26.33 in the next twelve months. This suggests that the stock has a possible downside of 9.9%.
View analysts' price targets for Supernus Pharmaceuticals
or view Wall Street analyst' top-rated stocks.

Who are some of Supernus Pharmaceuticals' key competitors?

What other stocks do shareholders of Supernus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Supernus Pharmaceuticals investors own include NVIDIA (NVDA), AbbVie (ABBV), Gilead Sciences (GILD), Alibaba Group (BABA), Exelixis (EXEL), Pfizer (PFE), GW Pharmaceuticals (GWPH), Netflix (NFLX), Corcept Therapeutics (CORT) and Cara Therapeutics (CARA).

Who are Supernus Pharmaceuticals' key executives?

Supernus Pharmaceuticals' management team includes the following people:
  • Mr. Jack A. Khattar, Founder, Pres, CEO, Sec. & Director (Age 59, Pay $1.49M)
  • Dr. Padmanabh P. Bhatt, Chief Scientific Officer & Sr. VP of Intellectual Property (Age 63, Pay $537.2k)
  • Ms. Tami T. Martin, Sr. VP of Regulatory Affairs (Age 65, Pay $450.28k)
  • Dr. Stefan K. F. Schwabe, Chief Medical Officer and Exec. VP of R&D (Age 68, Pay $584.04k)
  • Mr. James Patrick Kelly, Exec. VP & CFO (Age 54)
  • Dr. Todd Horich M.B.A., Ph.D., VP of Marketing
  • Mr. Taylor Raiford, VP of Sales
  • Dr. Bryan A. Roecklein, VP of Corp. Devel.
  • Mr. Frank Mottola, Sr. VP of Quality, GMP Operations & Information Technology (Age 48)
  • Dr. Jonathan Rubin, Sr. Vice-Pres of Clinical Research & Medical Affairs (Age 59)

What is Supernus Pharmaceuticals' stock symbol?

Supernus Pharmaceuticals trades on the NASDAQ under the ticker symbol "SUPN."

Who are Supernus Pharmaceuticals' major shareholders?

Supernus Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Scout Investments Inc. (0.55%), Prairiewood Capital LLC (0.08%), State of Alaska Department of Revenue (0.08%), Crossmark Global Holdings Inc. (0.03%) and 6 Meridian (0.02%). Company insiders that own Supernus Pharmaceuticals stock include Frederick M Hudson, Gregory S Patrick, Jack A Khattar and Stefan KF Schwabe.
View institutional ownership trends for Supernus Pharmaceuticals

Which major investors are selling Supernus Pharmaceuticals stock?

SUPN stock was sold by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue. Company insiders that have sold Supernus Pharmaceuticals company stock in the last year include Frederick M Hudson, Gregory S Patrick, and Stefan KF Schwabe.
View insider buying and selling activity for Supernus Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying Supernus Pharmaceuticals stock?

SUPN stock was purchased by a variety of institutional investors in the last quarter, including Prairiewood Capital LLC, Scout Investments Inc., Crossmark Global Holdings Inc., and 6 Meridian.
View insider buying and selling activity for Supernus Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Supernus Pharmaceuticals?

Shares of SUPN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Supernus Pharmaceuticals' stock price today?

One share of SUPN stock can currently be purchased for approximately $29.22.

How big of a company is Supernus Pharmaceuticals?

Supernus Pharmaceuticals has a market capitalization of $1.54 billion and generates $392.76 million in revenue each year. The specialty pharmaceutical company earns $113.06 million in net income (profit) each year or $2.10 on an earnings per share basis. Supernus Pharmaceuticals employs 464 workers across the globe.

What is Supernus Pharmaceuticals' official website?

The official website for Supernus Pharmaceuticals is www.supernus.com.

How can I contact Supernus Pharmaceuticals?

Supernus Pharmaceuticals' mailing address is 1550 E GUDE DR, ROCKVILLE MD, 20850. The specialty pharmaceutical company can be reached via phone at 301-838-2500 or via email at [email protected]

This page was last updated on 1/17/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.